Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX versus FOLFOX4 after prior irinotecan-based first-line therapy in metastatic colorectal cancer
2004-001685-40Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil, folinic acid and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Roche. Primary endpoint: Time to tumor progression or death. Started Oct 2004; status: completed.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-001685-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001685-40.